BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

...therapeutics company Highlight Therapeutics S.L appointed Carlos Pava as executive chairman; he was CEO of Immune Design Corp....
BioCentury | Feb 6, 2020
Deals

Beyond Keytruda: How Merck envisions innovation and growth after a spinout

...The company has also augmented its pipeline through its buyouts of Tilos Therapeutics Inc. and Immune Design Corp....
BioCentury | Oct 28, 2019
Finance

Nuvation Bio taking multimechanism approach with $275M series A

...at Radius Health Inc. (NASDAQ:RDUS); and CMO Sergey Yurasov, who was SVP and CMO of Immune Design Corp....
BioCentury | Jul 13, 2019
Product Development

Why Merck is in infectious disease for the long haul

...to develop diagnostics to detect antimicrobial resistance. In February, Merck announced a deal to acquire Immune Design Corp....
BioCentury | Apr 6, 2019
Finance

Room to rally in 2Q

...Nightstar Therapeutics plc (NASDAQ:NITE) 3/4/19 $877.0 NA NA $877.0 Merck & Co. Inc. ( NYSE:MRK) Immune Design Corp....
BioCentury | Feb 22, 2019
Company News

Merck to expand cancer vaccine tech portfolio with Immune Design bid

...Merck & Co. Inc. (NYSE:MRK) will acquire cancer vaccine company Immune Design Corp. (NASDAQ:IMDZ) to boost its cancer...
...20, before the deal was announced. Immune Design gained $4.40 (310%) to $5.82 on Feb. 21. Immune Design...
...unlikely to improve survival in synovial sarcoma (see "Immune Design Deprioritizes Synovial Sarcoma Compound CMB305" ). Immune Design's...
BioCentury | Feb 21, 2019
Company News

Merck to expand cancer vaccine tech portfolio with Immune Design bid

...Merck & Co. Inc. (NYSE:MRK) will acquire cancer vaccine company Immune Design Corp. (NASDAQ:IMDZ) to boost its cancer...
...$1.42 Wednesday, before the deal was announced. Immune Design gained $4.40 (310%) to $5.82 on Thursday. Immune Design...
...unlikely to improve survival in synovial sarcoma (see "Immune Design Deprioritizes Synovial Sarcoma Compound CMB305" ). Immune Design's...
BioCentury | Oct 12, 2018
Clinical News

Immune Design deprioritizes synovial sarcoma compound CMB305

...company will seek to partner CMB305 to explore further development of the compound in sarcoma. Immune Design...
...portfolio prioritization will extend its cash runway into 2021. In an Aug. 1 SEC filing, Immune Design...
...and the GLA-SE adjuvant. Immune Design previously reported interim data from the Phase II trial (see "Immune Design...
BioCentury | Jun 29, 2018
Product R&D

Highly personal

...also co-founded cancer synthetic lethality company Tango Therapeutics Inc., and Baltimore helped found immunotherapy companies Immune Design Corp....
...Inc., South San Francisco, Calif. Grail Inc., Menlo Park, Calif. Gritstone Oncology Inc., Emeryville, Calif. Immune Design Corp....
BioCentury | May 4, 2018
Clinical News

Immune Design reports Phase I OS data for CMB305 in STS

...In March, Immune Design Corp. (NASDAQ:IMDZ) reported data from 25 patients with cancer/testis antigen 1B (NY-ESO-1; CTAG1B)-positive soft...
...not yet been reached in the subset of 14 patients with synovial sarcoma. According to Immune Design...
...chemotherapeutic agents is 12.4-13.5 months for STS patients and 11.7 months for synovial sarcoma patients. Immune Design...
Items per page:
1 - 10 of 103
BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

...therapeutics company Highlight Therapeutics S.L appointed Carlos Pava as executive chairman; he was CEO of Immune Design Corp....
BioCentury | Feb 6, 2020
Deals

Beyond Keytruda: How Merck envisions innovation and growth after a spinout

...The company has also augmented its pipeline through its buyouts of Tilos Therapeutics Inc. and Immune Design Corp....
BioCentury | Oct 28, 2019
Finance

Nuvation Bio taking multimechanism approach with $275M series A

...at Radius Health Inc. (NASDAQ:RDUS); and CMO Sergey Yurasov, who was SVP and CMO of Immune Design Corp....
BioCentury | Jul 13, 2019
Product Development

Why Merck is in infectious disease for the long haul

...to develop diagnostics to detect antimicrobial resistance. In February, Merck announced a deal to acquire Immune Design Corp....
BioCentury | Apr 6, 2019
Finance

Room to rally in 2Q

...Nightstar Therapeutics plc (NASDAQ:NITE) 3/4/19 $877.0 NA NA $877.0 Merck & Co. Inc. ( NYSE:MRK) Immune Design Corp....
BioCentury | Feb 22, 2019
Company News

Merck to expand cancer vaccine tech portfolio with Immune Design bid

...Merck & Co. Inc. (NYSE:MRK) will acquire cancer vaccine company Immune Design Corp. (NASDAQ:IMDZ) to boost its cancer...
...20, before the deal was announced. Immune Design gained $4.40 (310%) to $5.82 on Feb. 21. Immune Design...
...unlikely to improve survival in synovial sarcoma (see "Immune Design Deprioritizes Synovial Sarcoma Compound CMB305" ). Immune Design's...
BioCentury | Feb 21, 2019
Company News

Merck to expand cancer vaccine tech portfolio with Immune Design bid

...Merck & Co. Inc. (NYSE:MRK) will acquire cancer vaccine company Immune Design Corp. (NASDAQ:IMDZ) to boost its cancer...
...$1.42 Wednesday, before the deal was announced. Immune Design gained $4.40 (310%) to $5.82 on Thursday. Immune Design...
...unlikely to improve survival in synovial sarcoma (see "Immune Design Deprioritizes Synovial Sarcoma Compound CMB305" ). Immune Design's...
BioCentury | Oct 12, 2018
Clinical News

Immune Design deprioritizes synovial sarcoma compound CMB305

...company will seek to partner CMB305 to explore further development of the compound in sarcoma. Immune Design...
...portfolio prioritization will extend its cash runway into 2021. In an Aug. 1 SEC filing, Immune Design...
...and the GLA-SE adjuvant. Immune Design previously reported interim data from the Phase II trial (see "Immune Design...
BioCentury | Jun 29, 2018
Product R&D

Highly personal

...also co-founded cancer synthetic lethality company Tango Therapeutics Inc., and Baltimore helped found immunotherapy companies Immune Design Corp....
...Inc., South San Francisco, Calif. Grail Inc., Menlo Park, Calif. Gritstone Oncology Inc., Emeryville, Calif. Immune Design Corp....
BioCentury | May 4, 2018
Clinical News

Immune Design reports Phase I OS data for CMB305 in STS

...In March, Immune Design Corp. (NASDAQ:IMDZ) reported data from 25 patients with cancer/testis antigen 1B (NY-ESO-1; CTAG1B)-positive soft...
...not yet been reached in the subset of 14 patients with synovial sarcoma. According to Immune Design...
...chemotherapeutic agents is 12.4-13.5 months for STS patients and 11.7 months for synovial sarcoma patients. Immune Design...
Items per page:
1 - 10 of 103